

MAIL STOP PCT

Attorney Docket: 26557U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Examiner: Unknown

YI, et al.

Group Art Unit: Unknown

International Application Number: PCT/KR2003/001534

Serial Number: Not Yet Assigned

International Filing Date: 30 July 2003 (30.07.2003)

Filed: February 2, 2005

For: **BENZOPYRAN DERIVATIVES SUBSTITUTED WITH SECONDARY AMINES
INCLUDING IMIDAZOLE, THEIR PREPARATION AND PHARMACEUTICAL
COMPOSITIONS CONTAINING THEM**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars:

[NOTE: One only of items a, b, c, and d must be checked.]

- [XXX] a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.
- [] b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.
The enclosed statement is accompanied by [check one]:
[] i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or
[] ii. a check in the amount required by 37 C.F.R. 1.17(p).
- [] c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.
[] Certification report(e) below; and
[] a check in the amount as required by 1.17(p).
- [] d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

Page 2

Attorney Docket: 26557U

[] e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

[] I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

[] I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

[] Appropriate certification is attached.

[~~XXX~~] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[~~XXX~~] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

or

[~~XXX~~] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and

Page 3

Attorney Docket: 26557U

return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,
NATH & ASSOCIATES PLLC

Date: February 2, 2005

NATH & ASSOCIATES PLLC
1030 15th Street, N.W., 6th Floor
Washington, D.C. 20005-1503
(202) 775-8383

By: 

Gary M. Nath
Registration Number 26,965
Joshua B. Goldberg
Registration Number 44,126
Customer Number 20529

GMN/JBG/le

FORM PTO-1449

INFORMATION DISCLOSURE CITATION

Attorney Docket:
26557USerial Number:
Not Yet AssignedInventor(s):
YI, et al.Filing Date:
February 2, 2005Group Art Unit:
Unknown

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
	A1	5,837,702 A	17 Nov. 1998	Rovnyak, et al.			30 Aug. 1994
	A2	5,629,429 A	13 May 1997	Kronenthal, et al.			07 Jun. 1995
	A3						
	A4						
	A5						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub-Class	Translation
	A6	0 648 758 A1	19 Apr. 1995	EP			N/A
	A7						
	A8						
	A9						
	A10						
	A11						
	A12						
	A13						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

A14 Grover, G.J., et al., "Pharmacologic Characterization of BMS-191095, a Mitochondrial K_{ATP} Opener with No Peripheral Vasodilator or Cardiac Action Potential Shortening Activity", The Journal of Pharmacology and Experimental Therapeutics, Vol. 297, No. 3, pp. 1184-1192, (2001).

A15 Ding, C.Z., et al., "Cardio selective Antiischemic ATP-Sensitive Potassium Channel (K_{ATP}) Openers. 6. Effect of Modifications at C6 of Benzopyranyl Cyanoguanidines", Journal of Medicinal Chemistry, Vol. 42, No. 18, pp. 3711-3717, (1999).

A16 Rovnyak, G.C., et al., "Cardio selective Antiischemic ATP-Sensitive Potassium Channel (K_{ATP}) Openers. 5. Identification of 4-(N-Aryl)-Substituted Benzopyran Derivatives with High Selectivity", Journal of Medicinal Chemistry, Vol. 40, No. 1, pp. 24-34, (1997).

A17

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.